Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2015 08:30 ET | Source: Aceragen, Inc.

Idera Announces Appointment of Joanna Horobin as Chief Medical Officer

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
November 09, 2015 08:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA...
November 06, 2015 07:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
November 05, 2015 10:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Presents Preclinical Data Demonstrating Potent Anti-Tumor Response From Combination Treatment With Intra-Tumoral IMO-2125 and Anti-PD-1 Monoclonal Antibody at AACR-NCI-EORTC International Conference

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA...
November 05, 2015 09:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom’s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting

- Poster Presentation to Reveal First Clinical Data for IMO-8400 as Potential Treatment for Waldenström’s Macroglobulinemia - CAMBRIDGE, Mass. and EXTON, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) --...
September 16, 2015 09:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Presents New Intratumoral IMO-2125 Preclinical Data at CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference

- First presentations of intratumoral IMO-2125 pre-clinical activity show induction of systemic antitumor immune responses resulting in tumor growth inhibition and changes in checkpoint gene...
September 04, 2015 12:00 ET | Source: Aceragen, Inc.

Idera to Present at the 22nd Annual NewsMakers in the Biotech Industry Conference

CAMBRIDGE, Mass. and EXTON, Pa., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
August 07, 2015 13:30 ET | Source: Aceragen, Inc.

Idera to Present at the 2015 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
August 06, 2015 07:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
June 29, 2015 08:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Appointment of Mark J. Casey as General Counsel and Secretary of the Board of Directors

CAMBRIDGE, Mass. and EXTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...